AbbVie Inc (ABBV)vsHinge Health, Inc. (HNGE)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
HNGE
Hinge Health, Inc.
$88.59
+0.37%
HEALTHCARE · Cap: $7.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 8842% more annual revenue ($64.39B vs $720.06M). HNGE leads profitability with a 15.1% profit margin vs 9.8%. HNGE trades at a lower P/E of 11.3x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
HNGE
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for HNGE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Revenue surging 53.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Weak financial health signals
Trading at 20.7x book value
ROE of -197.2% — below average capital efficiency
Earnings declined 68.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : HNGE
The strongest argument for HNGE centers on P/E Ratio, Revenue Growth, Debt/Equity. Profitability is solid with margins at 15.1% and operating margin at 19.0%. Revenue growth of 53.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : HNGE
The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while HNGE is a growth play — different risk/reward profiles.
HNGE is growing revenue faster at 53.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 52/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Hinge Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?